Loading stock data…
ARDX
$5.60+0.06 (+1.08%)
After Hours$5.70+0.10 (+1.79%)· Last close Jun 9
Ardelyx, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ardelyx, Inc. in the Healthcare sector is trading at $5.60 with a market capitalization of $1.3B. Wall Street consensus targets $16.33 (9 analysts), implying a +191.7% move over the next 12 months. The stock is currently 33% below its 52-week high of $8.40, remaining 8.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +191.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$5.60
Potential Downside
0%
Whystock Fair Value$5.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$16.33+191.7%
Range$13.00 – $19.00
Fundamentals
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritabl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.34B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.61
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.07%
Volume
Today's trading volume
2.98M
Recent News
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability. Chief Financia
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’
CFO said at a conference that profitability is “right around the corner,” though the company is waiting for more top-line certainty before formal guidance.
Should You Buy Ardelyx (ARDX)?
We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Ardelyx Inc. (NASDAQ:ARDX) ranks #9 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 30 Biotech company Ardelyx Inc. (NASDAQ:ARDX) is one of the recent additions in the Claude portfolio. Anthropic’s […]
Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis Patients - What's Changed
In early May 2026, Ardelyx presented a new long-term analysis at the National Kidney Foundation meetings showing that XPHOZAH (tenapanor) reduced serum phosphate in chronic kidney disease patients on dialysis without clinically meaningful changes in other electrolytes, nutrition markers, body mass, or blood pressure, reinforcing its safety profile as an add-on therapy. The extended NORMALIZE and OPTIMIZE data, together with Ardelyx’s peer exchange on XPHOZAH’s first-in-class mechanism,...
Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance
Ardelyx (ARDX) reported first quarter 2026 results, with revenue of US$94.47 million and a net loss of US$37.61 million, and reiterated full-year revenue guidance for IBSRELA and XPHOZAH. See our latest analysis for Ardelyx. Ardelyx’s latest earnings release and guidance update come after a strong 1 year total shareholder return of 91.89%, while the 30 day share price return of 18.93% suggests momentum has picked up again around US$7.10. If this earnings driven move has you looking beyond...